Construct and concurrent validation of the MG-QOL15 in the practice setting
Related Experiment Video
Updated: Jun 18, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Ted M Burns1, C K Grouse, Mark R Conaway
1Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, USA. tmb8r@virginia.edu
Abstract:
Health-related quality of life (HRQOL) estimates can play an important role in patient care by providing information about the patient's perception of impairment and disability and the degree to which the patient tolerates disease manifestations. The 15-item myasthenia gravis quality of life scale (MG-QOL15) is an HRQOL evaluative instrument specific to patients with myasthenia gravis (MG) that was designed to be easy to administer and interpret. In this multicenter study we demonstrate the construct validity of the MG-QOL15 in the practice setting. To assess the construct validity, score distributions were examined for test items in different MG patient groups that represent the clinical spectrum of the disease. For example, patients in remission more frequently scored test items as normal than did patients in other groups. Patients with lower (better) MG composite scores also more frequently scored items as normal than did patients with higher (worse) scores. There was also appropriate correlation between the MG-QOL15 and the other MG-specific scales studied. The study findings shed light on what troubles MG patients. The MG-QOL15 has construct validity in the clinical practice setting and represents an efficient and valuable tool for assessing HRQOL for patients with MG.
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Data Validation
Key parameters for method validation include:
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
Dosage Regimens: Designs and Approaches
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
